Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms × talazoparib × Clear all

Phase

Status

Completed 4 Recruiting 3 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 29 pembrolizumab 22 Cyclophosphamide 19 Paclitaxel 17 Irinotecan 17 Carboplatin 17 Fluorouracil 16 Docetaxel 16 Capecitabine 16 Leucovorin 13 Bevacizumab 12 fludarabine 11 Oxaliplatin 11 Everolimus 11 Pemetrexed 10 Erlotinib Hydrochloride 10 Dexamethasone 10 Rituximab 9 Cisplatin 9 Blood Specimen Collection 9 venetoclax 8 Cetuximab 8 Trastuzumab 7 Nivolumab 7 Sunitinib 6 Ipilimumab 6 Epoetin Alfa 6 Bortezomib 6 Azacitidine 6 trametinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04801966 2023-05-10

TAILOR

Peter MacCallum Cancer Centre, Australia

Phase NA Terminated

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡